FindTrial
Sign In

Effect of oral curcumin in improving ocular health

Efficacy of oral Curcumin in Ocular Surface Disease of Glaucoma Patients on topical therapy - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/063458
Enrollment
50
Registered
2024-03-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H42- Glaucoma in diseases classified elsewhere Health Condition 2: H404- Glaucoma secondary to eye inflammation

Interventions

Intervention1: nil: nil Intervention2: Laurica K capsule : One capsule a day f0r three months Will be given Orally. Curcumin act as anti inflammatory,anti oxidative agent in Ocular surface disease pa

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients willing to give consent for the study. Age more than equal to 18 years On 2 or more glaucoma drugs for at least 6 months showing some OSD. Ocular Surface Disease Index(OSDI) questionnarie more than 15.

Exclusion criteria

Exclusion criteria: Not willing to follow up Age less than 18 yrs Any patients with recent ocular surgery in past 3 months or secondary inflammatory conditions causing glaucoma eg,vernal keratoconjunctivitis(VKC),uveitis,sclerouveitis etc Any recent surgery in last 3 months

Design outcomes

Primary

MeasureTime frame
Objectiven Improvement in Ocular Surface Disease Index Score,Tear Break Up Time,Schiermer Timepoint: 4 Weeks 8 Weeks 12 Weeks—

Secondary

MeasureTime frame
Improvement in clinical parameters of patients like Intraocular Pressure & ocular surface analyzerTimepoint: 4 Weeks 8 Weeks 12 Weeks—

Countries

India

Contacts

Public ContactShikha Gupta

Aiims New Delhi

shikhagupta@aiims.edu01126593171

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026